| Date | Title | Description |
| 20.05.2022 | Athersys tries to post-hoc-analyze its way out of another trial fail for stroke stem cell therapy | Athersys’ stem cell therapy has failed yet again.
In a 206-person trial conducted in Japan, Athersys’ stem cell therapy for stroke failed its primary endpoint of “excellent outcome,” a combined measure of three stroke rec... |
| 25.06.2021 | For now, stem cells for Covid-19 are mostly a shot in the dark | The uncertainty over how to effectively treat Covid-19 is proving to be an opportunity for people interested in stem cells.
It is such a hot area that there are dozens of clinical trials underway testing different kinds of stem cells and ot... |
| 17.01.2020 | Peter Ciriello takes over the reins at Vygon USA; Mirum Pharmaceuticals taps Ian Clements to the role of CFO | Peter Ciriello
→ Peter Ciriello has climbed to the upper echelons of the French medical device maker Vygon Group. He will run the company’s US operations from the company’s headquarters in Pennsylvania and is also ta... |
| 17.01.2019 | Despite market uncertainty, healthcare CEOs of all stripes remain upbeat about 2019 | The market gyrations and the shutdown. The trade wars and global uncertainty.
None of the above has squashed the sunny optimism that a group of healthcare CEOs demonstrated at a roundtable discussion during the annual J.P. Morgan Healthcare... |
| 12.10.2018 | Meeting’s nearly fourfold attendance growth highlights cell, gene therapies’ rise | This was a far cry from the first meeting in 2006, when around 350 scientists huddled for warmth against a hostile world. Early gene therapies had ended in disaster, with the deaths of Jesse Gelsinger and others, and federal restrictions we... |
| 28.04.2014 | First efficacy trial of Athersys stem cell therapy yields disappointing interim results. So what now? | Cleveland-based Athersys (NASDAQ: ATHX) released the interim results today for the Phase 2 study it’s conducting with Pfizer. The randomized, double-blind, placebo-controlled study has enrolled 88 ulcerative colitis patients in the U.S., Ca... |
| 14.08.2013 | Stem cell firm Athersys faces enrollment struggles with one Phase 2 study; readies to begin another | Already the company has two Phase 2 trials in progress, although one has been held up by enrollment challenges. Athersys is working with Pfizer on a trial of MultiStem in treatment-resistant ulcerative colitis patients. Last time we checked... |
| 13.03.2013 | Stem cell company Athersys expects more R&D spending, potential partnerships in 2013 | Promoted
Covid-19’s terrible toll on diabetes patients. What can be done?
The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
| 04.04.2012 | Athersys awarded stem cell patent for graft-versus-host disease | The patent pertains to Athersys’ MultiStem technology, an off-the-shelf stem cell treatment derived from the bone marrow of adults or other nonembryonic sources. The technology has shown promise in reducing inflammation, protecting damaged ... |
| 02.04.2012 | Athersys CEO: Stroke therapy could be one of biggest blockbusters ever | So were Van Bokkelen’s bold pronouncements a legitimate assessment of MultiStem’s outlook, or just empty puffery from a small biotech on a shoe-string budget badly in need of corporate partners?
Steve Brozak, president of New Jersey-based r... |
| 27.03.2012 | Athersys gets OK for German solid organ transplant clinical trial | Enrollment will begin in the second half of the year and Athersys will provide “modest and limited” support, Van Bokkelen said.
Van Bokkelen provided updates on Athersys’ many clinical and preclinical programs with its MultiStem technology,... |
| 09.03.2012 | Stem cell company Athersys secures $9M in private stock sale | Athersys’ shares were trading down about 10 percent to $1.75 late Friday morning.
The company said it would use the proceeds from the private placement for “ongoing business development and clinical efforts, and for general corporate purpos... |
| 01.02.2012 | Athersys touts results of phase 1 blood diseases trial | Athersys made a similar announcement last May about the interim results of the trial.
The company’s next step in the GvHD application is to meet with regulators to discuss future plans for development, which could include a phase 2/3 trial,... |
| 01.02.2012 | Stem cell company Athersys gets grant to study traumatic brain injury | The grant will fund research that will include preclinical safety and efficacy studies required to support an Investigational New Drug (IND) application, as well as the clinical investigation of MultiStem to treat TBI.
Athersys’ MultiStem t... |
| 04.01.2012 | Athersys gets U.S. stem cell patent for heart attack, other conditions | “Cardiovascular disease represents an important opportunity area for MultiStem therapy, and [this] patent provides the company with additional protection for its product candidates in this high value area,” COO B.J. Lehmann said.
In August,... |
| 16.11.2011 | Covidien beats The Street, confirms 2012 guidance | Earnings Roundup | Covidien (NYSE:COV) beat Wall Street’s earnings expectations for both its fourth quarter and 2011 fiscal year, sending shares up 1.8 percent today.
The Mansfield, Mass.-based health care giant’s medical device segment once again led the cha... |
| 14.11.2011 | Athersys closes $20 million stock purchase deal with Aspire Capital | “We have historically obtained capital through a combination of business partnerships, grant funding and equity financings,” Athersys President and COO B.J. Lehmann said in a statement. “This agreement provides us additional flexibility to ... |
| 10.08.2011 | Athersys prepares for stroke, heart attack phase 2 clinical trials | Stem cell therapy developer Athersys (NASDAQ:ATHX) plans to begin phase 2 clinical trials of its MultiStem therapy for stroke and heart attack patients by the end of the year.
Moving ahead with its stroke therapy is key for Athersys because... |
| 28.01.2011 | Athersys to raise $13M in direct offering; shares tumble | “Shareholder dilution is just kind of a reality for an early stage biotech,” said Lauren Migliore, an equities analyst with Morningstar in Chicago.
The company was vague about its plans for the sale’s proceeds, saying the cash would be used... |
| 28.01.2011 | Athersys looks to raise $13.1 million in private offering | Stem cell company Athersys Inc. (NSDQ:ATHX) has reached an agreement to sell about $13 million of its shares to unidentified private investors.
Athersys will raise the cash by selling about 4.4 million shares of its common stock and warrant... |
| 03.01.2011 | Ex-Cleveland Clinic CEO Floyd Loop leaves Athersys board | Loop joined Athersys’ board in 2007, after retiring from Cleveland Clinic in 2004. When he started as the Clinic’s CEO in 1989, the hospital system consisted only of the Clinic’s main East Side campus and had annual revenues south of $600 m... |
| 18.11.2010 | Analyst: Athersys poised for stroke market with MultiStem | The most promising application of Athersys Inc.’s (NSDQ:ATHX) stem cell technology lies in treating stroke victims, according to a Morningstar Inc. analyst.
“It’s really market potential that leads us to believe that stroke is the most prom... |
| 10.09.2010 | Athersys loses VC board member | A member of stem cell company Athersys Inc.’s (NDSQ:ATHX) board of directors has resigned.
As of Sept. 9, Michael Sheffery, a general partner with New York-based venture firm OrbiMed Advisors, no longer is a member of the Athersys board, ac... |
| 24.05.2010 | Athersys stem cell therapy wins scientists’ plaudits | By Mary Vanac
Doctors and researchers at the Athersys Inc. (NSDQ:ATHX) investor meeting in New York City expressed hope that the company’s stem cell therapy — MultiStem — could raise the ceiling on care for heart attack, stroke and some can... |
| 15.05.2010 | Experts laud potential of Athersys stem cell therapy MultiStem | “We and a growing number of others believe that MultiStem represents a significant advance in the field of regenerative medicine,” Gil Van Bokkelen, chairman and chief executive of Athersys, told his audience. That’s because “it’s a drug-li... |
| 22.02.2010 | OrbiMed Advisors raises $550M for health venture fund | Last year, OrbiMed led a $25 million Series B round for Oakwood-based ViewRay, which is developing a device that uses MRIs to guide gamma rays to target cancerous tumors. OrbiMed lists Cleveland-based stem cell developer Athersys as one of ... |
| 16.02.2010 | Athersys finishes enrolling heart attack patients for stem cell therapy study | Athersys plans to use catheters to deliver its MultiStem therapy to the damaged regions of patients’ hearts during its studies at several U.S. cardiovascular treatment centers, including the Cleveland Clinic, Columbia University Medical C... |
| 10.02.2010 | Athersys gets U.S., European patents for investigational stem cell therapy | Athersys said Wednesday it has been granted U.S. patent 7,659,118, which covers its non-embryonic, multipotent stem cells and how they are isolated, expanded, made into a therapy and used. The Cleveland company also received EP1218489B1, ... |
| 14.01.2010 | Biopharmaceutical company Athersys seeks to register 20 million shares, warrants for future sale | If Athersys did sell shares or warrants — promises to sell shares at a certain price on a future date — it would use the “net proceeds from the sale of securities for general corporate purposes, including, but not limited to, research and d... |
| 04.01.2010 | University of Cincinnati students experiment with medical device design — MedCity Evening Read, Jan. 4, 2010 | A new and improved Hillcrest Hospital should be up and running by this time next year, thanks to a $163 million expansion project at the Cleveland Clinic hospital in Mayfield Heights, according to the Willoughby News-Herald.Â
An Ohio law... |
| 23.12.2009 | Athersys therapy ‘good fit’ for Pfizer Regenerative Medicine, says chief scientific officer | On Monday, the Pfizer unit struck a development and commercialization agreement with Athersys Inc., the Cleveland biopharmaceutical company. Pfizer plans to develop and market a therapy for sufferers of inflammatory bowel disease based on M... |
| 22.12.2009 | New tax on medical device manufacturers could force Invacare to ship out jobs — MedCity Evening Read, Dec. 22, 2009 | Nationwide Children’s Hospital in Columbus recently was awarded an initial $5.5 million contract from the National Cancer Institute to serve as a biospecimen core resource for the Cancer Genome Atlas, a program co-managed by the cancer in... |
| 21.12.2009 | Athersys Inc. shares more than double on Pfizer agreement to develop inflammatory bowel disease therapy | “We think that having Pfizer as our partner is an important statement about the quality of the work that we’re doing, the strength of our science and technology, the distinctive profile of our stem cell platform and ultimately what it might... |
| 08.12.2009 | Cleveland Clinic gets grants, license agreement, invests in digital medicine — MedCity Evening Read, Dec. 8, 2009 | Promoted
Telemedicine’s potential to provide healthcare to the world’s most vulnerable
Teladoc Health Head of R&D Yulun Wang highlights the impact of virtual care in underserved populations around the globe through the World Telehealth ... |
| 02.12.2009 | MedCity News on WKYC-TV: The future of Cleveland biopharma’s ‘poster child’ | Athersys said last month that it continued enrollments in safety and efficacy trials for MultiStem, which would be used for heart attack patients and those who run the risk of rejecting bone marrow transplants. At the same time, the clinica... |
| 06.11.2009 | Athersys still looking for funders of stem cell study for stroke patients | CLEVELAND, Ohio — Athersys Inc. continued enrollments during the third quarter in safety and efficacy trials of its adult stem cell therapy, MultiStem, for heart attack patients and those who run the risk of rejecting bone marrow transplan... |
| 13.08.2009 | Words to lead by: Retired Cleveland Clinic CEO Floyd Loop writes book on leadership, medicine | Dr. Loop retired from the Cleveland Clinic in October 2004 after leading the health care system for 15 years. Loop ascended to the executive suite as an internationally recognized heart surgeon, according to his Forbes.com profile.  He pr... |
| 10.03.2009 | Pappas Ventures closes $102 million life science fund | “We have long been intrigued by the medical research activity in places like Indiana and Ohio,” said Worthy, who described the states as “underserved areas” along with Texas, Tennessee and Florida.
With this closing, Pappas has $350 million... |
| 12.06.2007 | Cleveland biotech Athersys raises $65M with reverse-merger | Athersys, a Cleveland, Ohio biotech, went public via reverse merger and raised $65 million in a private placement. The company’s release is here.
Founded in 1995, Athersys is active in a bewildering number of areas. Its lead product candida... |
| - | Athersys CEO: Stroke therapy could be one of biggest blockbusters ever | Gil Van Bokkelen, CEO of stem cell company Athersys (NASDAQ:ATHX), is typically one to speak in cautious and measured tones, but he made a brash statement in the company’s most recent quarterly earnings call.
Van Bokkelen said Cleveland-bas... |
| - | Words to lead by: Retired Cleveland Clinic CEO Floyd Loop writes book on leadership, medicine | Updated 3:57 p.m. Friday, Aug. 14, 2009
CLEVELAND, Ohio – Health care reform, rising costs, falling reimbursements, tough financial markets and burgeoning patient demand are combining to cause a storm-of-the-century in the health care... |
| - | MedCity News on WKYC-TV: The future of Cleveland biopharma’s ‘poster child’ | Mary Vanac, MedCity News’ vice president and Ohio bureau chief, joined syndication partner WKYC-TV Tuesday evening discussing the future of Athersys, a Cleveland stem cell company that continues to search for partners as it develops its adu... |
| - | Athersys closes $20 million stock purchase deal with Aspire Capital | A new common stock purchase agreement with Aspire Capital Fund LLC will give Cleveland biopharmaceutical company Athersys (NASDAQ:ATHX) up to $20 million in investment dollars.
Chicago-based Aspire has committed to purchasing up to $20 mill... |
| - | Athersys awarded stem cell patent for graft-versus-host disease | Stem cell developer Athersys (NASDAQ:ATHX) has received a U.S patent that covers the use of nonembryonic, multipotent stem cells in the treatment of graft-versus-host disease.
Graft-versus-host disease (GvHD) often occurs after a stem cell ... |
| - | New tax on medical device manufacturers could force Invacare to ship out jobs — MedCity Evening Read, Dec. 22, 2009 | News and notes from the day in MedCity, Ohio:
A new tax on medical device manufacturers in the U.S. Senate’s health insurance reform bill may force Elyria-based Invacare Corp., which employs 1,300 people in Northeast Ohio, to shift jobs to ... |
| - | Biopharmaceutical company Athersys seeks to register 20 million shares, warrants for future sale | CLEVELAND, Ohio — Biopharmaceutical company Athersys Inc. is seeking to register 20 million shares of common stock, or warrants to buy the stock, which the company might or might not sell in the future.
The so-called “shelf registration” fi... |
| - | OrbiMed Advisors raises $550M for health venture fund | NEW YORK, New York — OrbiMed Advisors, which has invested in Ohio companies Athersys Inc. and ViewRay, has raised $550 million for its latest health venture capital fund.
The company’s Caduceus Private Investments IV fund will be its larges... |
| - | Athersys gets U.S. stem cell patent for heart attack, other conditions | Athersys (NASDAQ:ATHX) has obtained a U.S. patent that covers the use of nonembryonic multi-potent stem cells for the treatment of several heart conditions, including heart attack.
The patent provides protection for “multiple techniques” fo... |
| - | Athersys finishes enrolling heart attack patients for stem cell therapy study | CLEVELAND, Ohio –Â Biopharmaceutical company Athersys Inc. has finished enrolling patients for a Phase 1 clinical trial of its MultiStem adult stem cell therapy to treat heart attack victims.
Athersys expects to begin getting results of the... |
| - | Pappas Ventures closes $102 million life science fund | North Carolina-based Pappas Ventures closed its fourth fund, a $102 million round that will invest in “product-oriented biopharmaceutical companies, with a secondary focus on medical technologies,” according to a news release.
Pappas expect... |
| - | Stem cell firm Athersys faces enrollment struggles with one Phase 2 study; readies to begin another | Thanks in part to a SBIR Fast Track grant worth up to $2.8 million, stem cell company Athersys (Nasdaq: ATHX) is gearing up to advance its third MultiStem program into Phase 2 clinical trials.
Cleveland-based Athersys develops an off-the-sh... |
| - | Meeting’s nearly fourfold attendance growth highlights cell, gene therapies’ rise | The Alliance for Regenerative Medicine’s (ARM’s) annual Cell and Gene Meeting needs a bigger boat. Now in its 13th year, the conference attracted more than 1,200 people to Torrey Pines Mesa in San Diego, from October 3 to 5. Last year it dr... |
| - | Athersys Inc. shares more than double on Pfizer agreement to develop inflammatory bowel disease therapy | Updated 5:00 p.m.
CLEVELAND, Ohio — Biopharmaceutical company Athersys Inc. is in line for up to $111 million in revenue through an agreement with a Pfizer Inc. unit to develop and market a stem cell therapy for patients who suffer from in... |
| - | Experts laud potential of Athersys stem cell therapy MultiStem | Doctors and researchers at the Athersys Inc. (NASDAQ: ATHX) investor meeting in New York City expressed hope that the company’s stem cell therapy — MultiStem — could raise the ceiling on care for heart attack, stroke and some cancer patient... |
| - | Despite market uncertainty, healthcare CEOs of all stripes remain upbeat about 2019 | The market gyrations and the shutdown. The trade wars and global uncertainty.
None of the above has squashed the sunny optimism that a group of healthcare CEOs demonstrated at a roundtable discussion during the annual J.P. Morgan Healthcare... |
| - | Cleveland Clinic gets grants, license agreement, invests in digital medicine — MedCity Evening Read, Dec. 8, 2009 | The Cleveland Clinic has received a $2.75 million federal grant to study the use of stem cells in treating multiple sclerosis, Crain’s Cleveland Business reported today. The four-year grant from the Department of Defense will fund a 24-pati... |
| - | Stem cell company Athersys secures $9M in private stock sale | Stem cell developer Athersys (NASDAQ:ATHX) has secured $9 million in a private placement with an unidentified investor.
Cleveland-based Athersys said it would issue about 4.3 million shares of common stock and an equal number of warrants to... |
| - | Athersys prepares for stroke, heart attack phase 2 clinical trials | Stem cell therapy developer Athersys (NASDAQ:ATHX) plans to begin phase 2 clinical trials of its MultiStem therapy for stroke and heart attack patients by the end of the year.
Moving ahead with its stroke therapy is key for Athersys because... |
| - | First efficacy trial of Athersys stem cell therapy yields disappointing interim results. So what now? | Edited to include comments from CEO.
Halfway through its first large-scale efficacy trial, Athersys’s experimental stem cell therapy did not provide significant benefit to patients with moderate-to-severe ulcerative colitis.
But the company... |
| - | Ex-Cleveland Clinic CEO Floyd Loop leaves Athersys board | Floyd Loop, the former Cleveland Clinic CEO credited with turning around the once-struggling hospital, has resigned from the board of stem cell company Athersys Inc. (NASDAQ:ATHX).
Athersys didn’t say why Loop resigned from the board, excep... |
| - | Athersys to raise $13M in direct offering; shares tumble | Stem cell company Athersys Inc. (NASDAQ:ATHX) has reached an agreement to sell about $13 million of its shares to unidentified private investors.
Athersys will raise the cash by selling about 4.4 million shares of its common stock and warra... |
| - | Athersys gets U.S., European patents for investigational stem cell therapy | Updated 4:39 p.m.
CLEVELAND, Ohio — Biopharmaceutical company Athersys Inc. has received two patents that extend protection of its investigational stem cell therapy and how it is produced and used.
Athersys said Wednesday it has been gra... |
| - | Stem cell company Athersys gets grant to study traumatic brain injury | Stem cell developer Athersys (NASDAQ:ATHX) has received $3.6 million in new grant funding, with one of the grants going toward studying its MultiStem technology for the treatment of traumatic brain injury.
A $1.9 million grant to study trau... |
| - | Athersys touts results of phase 1 blood diseases trial | Stem cell therapy developer Athersys (NASDAQ:ATHX) reported positive results from a phase 1 clinical trial in patients with leukemia and similar blood diseases.
The trial showed that the company’s MultiStem technology may reduce the inciden... |
| - | Stem cell company Athersys expects more R&D spending, potential partnerships in 2013 | Cleveland-based Athersys (NYSE:ATHX) has a full plate as it continues to advance its “off the shelf” stem cell therapy, MultiStem, through clinical trials in several indications. That means shareholders can expect more R&D spending and ... |
| - | University of Cincinnati students experiment with medical device design — MedCity Evening Read, Jan. 4, 2010 | News and notes from the day in MedCity, Ohio:
Danielle Everman had never heard of pelvic prolapse until she started the Medical Device Innovation and Entrepreneurship Program at the University of Cincinnati, according to the Business Courie... |
| - | Athersys gets OK for German solid organ transplant clinical trial | Stem cell developer Athersys (NASDAQ:ATHX) has received German regulatory clearance for a physician-sponsored solid organ transplant clinical trial.
The study will enroll up to 24 patients and examine Athersys’ MultiStem technology in reduc... |
| - | Athersys therapy ‘good fit’ for Pfizer Regenerative Medicine, says chief scientific officer | CLEVELAND, Ohio — Ruth McKernan helped start Pfizer Regenerative Medicine — a research-oriented business unit of Pfizer, which calls itself the world’s largest research-based pharmaceutical company — in July 2008.
“We see regenerative medic... |
